Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$12.06
-0.25 (-2.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-14.0M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
28.7x
↑EV/EBITDA
14.1x
↑ROE
8.7%
↑Gross Margin
55.6%
↑Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.4%
FCF CAGR
—
FCF margin
9.1%
FCF / Net income
0.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.24B · net income $304.9M · FCF $112.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.24B | $1.24B | $1.24B | $1.09B | $1.42B |
| Net Income | $304.9M | $304.9M | $309.2M | $192.3M | $383.7M |
| EBITDA | $563.4M | $563.4M | $550.2M | $382.8M | $525.3M |
| EPS | 0.51 | 0.51 | 0.52 | 0.32 | 0.70 |
| Gross Margin | 55.6% | 55.6% | 58.4% | 59.9% | 66.0% |
| Operating Margin | 31.0% | 31.0% | 27.9% | 19.9% | 29.7% |
| Net Margin | 24.6% | 24.6% | 24.9% | 17.6% | 27.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.56 | 0.58 | 0.24 |
| Current Ratio | 2.08 | 2.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $112.8M | $112.8M | $-14.0M | $-84.6M | $-2.9M |
| Returns | |||||
| ROE | 8.7% | 8.7% | 9.6% | 6.6% | 14.9% |
| Valuation | |||||
| P/E | 28.71 | 28.71 | 27.38 | 35.19 | 20.61 |
| EV/EBITDA | 14.07 | 14.07 | 16.34 | 18.14 | 15.19 |
| P/B | 2.07 | 2.07 | 2.63 | 2.34 | 3.08 |
| Growth & Yield | |||||
| Revenue Growth | -0.5% | -0.5% | 13.6% | -22.8% | — |
| EPS Growth | -1.9% | -1.9% | 62.5% | -54.3% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
28.0%
EPS terminal req.
$1.07
Spread vs growth
-29.9%
5Y implied EPS CAGR
20.5%
EPS terminal req.
$1.29
Spread vs growth
-22.4%
10Y implied EPS CAGR
15.1%
EPS terminal req.
$2.09
Spread vs growth
-17.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.9%
Start / end P/E
29.7x → 23.6x
EPS bridge
0.52 → 0.51
Residual
+0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.